The transporter “variome”: The missing link between gene variants and bile salt transporter function
Roman Müllenbach, Frank Lammert – 28 January 2009
Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation
Eva U. Sotil, Jeanne Gottstein, Edgar Ayala, Christopher Randolph, Andres T. Blei – 28 January 2009 – In the current Model for End‐Stage Liver Disease allocation system, patients are at risk of suffering repeated episodes of hepatic encephalopathy (HE) while waiting for an orthotopic liver transplantation (OLT); the posttransplantation impact of these episodes has not been well explored.
The importance of hepatic encephalopathy: Pre‐transplant and post‐transplant
Andrea DiMartini, Kapil Chopra – 28 January 2009
Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard‐dose or reduced‐dose tacrolimus in liver transplant recipients
Björn Nashan, Faouzi Saliba, Francois Durand, Rafael Barcéna, Jose Ignacio Herrero, Gilles Mentha, Peter Neuhaus, Matthew Bowles, David Patch, Angel Bernardos, Jürgen Klempnauer, René Bouw, Jane Ives, Richard Mamelok, Diane McKay, Matt Truman, Paul Marotta – 28 January 2009 – The pharmacokinetics of mycophenolate mofetil (MMF) in liver transplant recipients may change because of pharmacokinetic interactions with coadministered immunosuppressants or because changes in the enterohepatic anatomy may affect biotransformation of MMF to mycophenolic acid (MPA) and enterohepatic recirculation of M
Vascular endothelial growth factor receptor 2 expression in non‐tumorous cirrhotic liver is higher when hepatoma is beyond milan criteria
Federico Aucejo, Richard Kim, Nizar Zein, Cristiano Quintini, Teresa Diago Uso, Rocio Lopez, Bijan Eghtesad, John Fung, Charles Miller, Lisa Yerian – 28 January 2009 – Hepatocellular carcinoma (HCC) is a highly vascular tumor. Angiogenesis in HCC is mediated at least in part by vascular endothelial growth factor (VEGF), which is expressed in HCC and surrounding cirrhotic tissue.
Splenic artery occlusion for small‐for‐size syndrome: Better late than never but early is the best
Chung‐Mau Lo – 28 January 2009
Fibrogenesis in pediatric cholestatic liver disease: Role of taurocholate and hepatocyte‐derived monocyte chemotaxis protein‐1 in hepatic stellate cell recruitment
Grant A. Ramm, Ross W. Shepherd, Anita C. Hoskins, Sonia A. Greco, Agnieszka D. Ney, Tamara N. Pereira, Kim R. Bridle, James D. Doecke, Peter J. Meikle, Bruno Turlin, Peter J. Lewindon – 28 January 2009 – Cholestatic liver diseases, such as cystic fibrosis (CF) liver disease and biliary atresia, predominate as causes of childhood cirrhosis. Despite diverse etiologies, the stereotypic final pathway involves fibrogenesis where hepatic stellate cells (HSCs) are recruited, producing excess collagen which initiates biliary fibrosis.
A new section: Image of the month
Keith D. Lindor – 28 January 2009
Alanine aminotransferase isoenzymes: Molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity
Rong‐Ze Yang, Soohyun Park, William J. Reagan, Rick Goldstein, Shao Zhong, Michael Lawton, Francis Rajamohan, Kun Qian, Li Liu, Da‐Wei Gong – 28 January 2009 – The elevation of serum alanine aminotransferase (ALT) is regarded as an indicator of liver damage based on the presumption that ALT protein is specifically and abundantly expressed in the liver. However, ALT elevation is also observed in non–liver injury conditions (for example, muscle injury) and in apparently healthy people.